Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Makers Want More Protections For Collecting Off-Label Data

This article was originally published in The Gray Sheet

Executive Summary

Government agencies should create a safe harbor where industry can collect post-market clinical data without fear of being perceived as promoting off-label use, industry speakers said at the Transcatheter Cardiovascular Therapeutics conference in San Francisco last month
Advertisement

Related Content

FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’
FDA Issues Guidance On Off-Label Info; Waxman Seeks ‘Re-examination’

Topics

Advertisement
UsernamePublicRestriction

Register

MT027988

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel